Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (VKTX) announced it will release its financial results for Q2 2020 on July 29, 2020, after market close. The company will host a conference call at 4:30 PM ET to discuss the results and corporate updates. Stakeholders can join via phone or listen online. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for NASH and VK5211 for hip fracture recovery. The company holds five therapeutic programs licensed from Ligand Pharmaceuticals.